Branaplam + Placebo
Phase 2Terminated 0 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Early Manifest Huntington Disease
Conditions
Early Manifest Huntington Disease
Trial Timeline
Dec 8, 2021 → Oct 27, 2023
NCT ID
NCT05111249About Branaplam + Placebo
Branaplam + Placebo is a phase 2 stage product being developed by Novartis for Early Manifest Huntington Disease. The current trial status is terminated. This product is registered under clinical trial identifier NCT05111249. Target conditions include Early Manifest Huntington Disease.
What happened to similar drugs?
2 of 20 similar drugs in Early Manifest Huntington Disease were approved
Approved (2) Terminated (2) Active (17)
❌PERT-IJS plus trastuzumab, carboplatin and docetaxel + Perjeta plus trastuzumab, carboplatin and docetaxelBioconPhase 3
🔄SHR-A1811 for Injection + Docetaxel injection + Trastuzumab Injection + Carboplatin for Injection + Pertuzumab InjectionJiangsu Hengrui MedicinePhase 3
🔄SHR7280；Ganirelix Acetate Injection simulant + SHR7280 simulant； Ganirelix Acetate InjectionJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05111249 | Phase 2 | Terminated |
Competing Products
20 competing products in Early Manifest Huntington Disease